About Contact Us Careers
Sign In

Somatostatin Analogs Market - Top Companies and Manufacturers

  • Report ID: 5047
  • Published Date: Jan 03, 2025
  • Report Format: PDF, PPT

Companies Dominating the Somatostatin Analogs Landscape

    • Novartis AG
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Sun Pharmaceutical Industries Ltd
    • Midatech Pharma PLC
    • Ipsen Pharma, Chiasma Inc.
    • Peptron, Inc
    • CRINETICS PHARMACEUTICALS
    • Dauntless Pharmaceuticals
    • Camurus AB
    • Pfizer Inc.
Browse Key Market Insights with Data Illustration:

In the News

  • Novartis AG announced that it has received a favorable opinion for Pluvicto a radioligand therapy, in combination with androgen deprivation therapy (ADT) for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC). Furthermore, the positive opinion is based on data from the Phase III VISION study, which would significantly improve overall survival in PSMA-positive mCRPC patients and provide transformative innovation to more patients around the world.
  • Sun Pharmaceutical Industries Ltd. teamed up with Philogen SpA for the commercialization of Nidlegy, a brand-new immunotherapy drug that Philogen is creating to treat both melanoma and non-melanoma skin cancers in New Zealand, Australia, and Europe.

Author Credits:  Radhika Pawar


  • Report ID: 5047
  • Published Date: Jan 03, 2025
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of somatostatin analogs is evaluated at USD 8.03 billion.

The somatostatin analogs market size was over USD 7.57 billion in 2024 and is poised to exceed USD 18.69 billion by 2037, witnessing over 7.2% CAGR during the forecast period i.e., between 2025-2037. Rising prevalence of Cushing syndrome and growing launch of advanced drug therapies for rare diseases will drive the market growth.

North America industry is anticipated to account for largest revenue share of 49% by 2037, due to availability of key players such as Pfizer Inc. and Novartis AG in the region.

The major players in the market are Novartis AG, Sun Pharmaceutical Industries Ltd, Midatech Pharma PLC, Ipsen Pharma, Chiasma Inc., Peptron, Inc., CRINETICS PHARMACEUTICALS, Dauntless Pharmaceuticals, Camurus AB, Teva Pharmaceuticals Inc, and Pfizer Inc.
Inquiry Before Buying Request Free Sample

Copyright © 2025 Research Nester. All Rights Reserved

logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample